Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05864144 · ClinicalTrials.gov registry record · Phase 1
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Sensei Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 10
- Study locations
NCT05864144: Active Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Sensei Biotherapeutics.
NCT05864144 is a Phase 1 study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by Sensei Biotherapeutics. The registered enrollment target is 98 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05864144, a Phase 1 study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by Sensei Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Primary Outcome
Incidence, nature and severity of treatment-related adverse events
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG SNS-101 (anti-VISTA)
Study Locations (10)
Texas
- NEXT Oncology Dallas - Irving
- South Texas Accelerated Research Therapeutics (START) San Antonio - San Antonio
California
- UCLA Hematology/Oncology - Los Angeles
Colorado
- University of Colorado Cancer Center - Anschutz Medical - Aurora
Kentucky
- Norton Healthcare - Louisville
Michigan
- Henry Ford Cancer - Detroit
New York
- Icahn School of Medicine at Mt. Sinai - New York
Pennsylvania
- University of Pennsylvania, Perelman Center for Advanced Medicine - Philadelphia
South Dakota
- Sanford Cancer Center - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What the registry record for NCT05864144 still lists
NCT05864144 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT05864144 lists 10 locations in 9 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05864144 about?
NCT05864144 is a clinical study titled "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors". Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
What is the current status of trial NCT05864144?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2023-05-31. Estimated completion is 2027-06.
What conditions does trial NCT05864144 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Pancreatic Cancer, Head and Neck Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT05864144?
The interventions under investigation include: Cemiplimab (DRUG), SNS-101 (anti-VISTA) (DRUG).
Who is sponsoring clinical trial NCT05864144?
This trial is sponsored by Sensei Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05864144 being conducted?
This trial has 10 study locations across California, Colorado, Kentucky, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05864144's enrollment target sits among peer trials
98 598th of 1224 higher than 622 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
- NCT04860141 · 98 participants · Phase 4
Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI